Cellectar Biosciences (CLRB) Says it Was Granted FDA Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

May 9, 2018 2:29 PM

Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found